Objectives: To determine the population structure and genetic relatedness of plasmids encoding CMY-2 b-lactamase in clinical Escherichia coli from humans and companion animals within a defined geographical area.
Introduction
CMY-2 is the most commonly reported plasmid-encoded AmpC b-lactamase in Escherichia coli and other Enterobacteriaceae from different host species worldwide. 1 Although less frequently reported compared with extended-spectrum b-lactamases (ESBLs), CMY-2 is clinically relevant since, like ESBLs, it inactivates third-generation cephalosporins and may mediate resistance to carbapenems in combination with loss of outer membrane porins. 2 A recent study emphasized the possible risk of transmission of bla CMY-2 from poultry to humans. 3 Current knowledge about possible exchange of plasmids harbouring bla CMY-2 between humans and animals is limited to studies examining bacterial isolates from humans, food-producing animals and food. 4 -6 Despite the widespread occurrence of bla CMY-2 in E. coli isolates from dogs and cats worldwide, 7 -9 zoonotic spread of this b-lactam resistance determinant from companion animals has received scarce attention to date. To shed light on this potential zoonotic risk, population structure and genetic relatedness of plasmids carrying bla CMY-2 were investigated in clinical E. coli isolated from humans, dogs and cats within a defined geographical area.
Methods
E. coli displaying an AmpC phenotype (i.e. resistance to cefoxitin and thirdgeneration cephalosporins and susceptibility to cefepime) were isolated from community-dwelling human patients (n ¼ 42), dogs (n ¼ 11 and sequencing (Macrogen Inc.). The sequence of a novel bla CMY variant (GenBank accession number KF564 648) was determined using forward primers ISEcp1/F and ecpF2 12 and reverse primer blaCMY/R (5 ′ -ATACCCGGAATAGCCTGCTC-3 ′ ), and forward primer blaCMY/F (5 ′ -GGGTGCATAAAACGGGATCC-3 ′ ) and reverse primer blc/R (5 ′ -GACAACCAGGAATGCAGC-3 ′ ). Plasmid DNA was isolated from bla CMY-2 -positive isolates by alkaline lysis and transformed into electrocompetent Genehog E. coli (Invitrogen). Transformants were selected on BHI agar (Merck) supplemented with cefotaxime (2 mg/L), tested by colony PCR to confirm the presence of bla CMY-2 and by S1 nuclease PFGE to determine plasmid content and size. 13 Transformants positive for bla CMY-2 and carrying a single plasmid were further characterized by PCR-based replicon typing (PBRT; Diatheva) and plasmid multilocus sequence typing (pMLST) (http://pubmlst.org/ plasmid/). Plasmid types shared by different host species were further analysed by restriction fragment length polymorphism (pRFLP) using FastDigest w EcoRV and FastDigest w PstI enzymes (Thermo Scientific). Susceptibility to ciprofloxacin, gentamicin, imipenem, trimethoprim/sulfamethoxazole and tetracycline was determined for all transformants by disc diffusion according to CLSI standards.
14,15 Transferability of bla CMY-2 -positive plasmids was tested by filter-mating experiments using rifampicin-resistant E. coli K12 J62-2 as recipient. Transconjugants were selected on BHI agar containing cefotaxime (2 mg/L) and rifampicin (50 mg/L), and tested by PCR to confirm the presence of bla CMY-2 .
Results
Six (14%), 56 (86%) and 6 (75%) isolates from humans, dogs and cats, respectively, were positive for bla CMY-2 . Furthermore, two (5%) human isolates harboured a novel CMY gene variant, which was assigned bla CMY-108 (http://www.lahey.org/studies). No acquired AmpC genes were detected in the remaining 45 isolates.
A plasmid origin was demonstrated for 93% of the bla CMY-2 -positive isolates and 53 (78%) of the plasmids were transferable by conjugation. In contrast, bla CMY-108 was most likely located on the chromosome since repeated transformation and conjugation attempts were unsuccessful. Three transformants harboured multiple plasmids and were not further analysed. The remaining 60 plasmids ranged in size from 45 to 104 kb and harboured IncI1 (n ¼ 31; 52%), IncA/C (n ¼ 8; 13%), IncFII (n ¼ 6; 10%), IncI2 (n ¼ 3; 5%), IncL/M (n ¼ 2; 3%) and IncB/O (n ¼ 1; 2%) replicons. Nine (15%) plasmids were non-typeable by PBRT. IncI1 was detected in all three host species, IncFII in both humans and dogs, IncL/M in humans only, and IncA/C, IncI2, IncB/O and non-typeable plasmids in dogs only ( Table 1) .
Subtyping of IncI1 plasmids showed six known sequence types (ST2, ST12, ST18, ST20, ST23 and ST26) and six new sequence types (ST120, ST121, ST122, ST123, ST124 and ST125) resulting both from novel combinations of known alleles and detection of new alleles. Four (13%) IncI1 plasmids were not typeable as the sogS allele was not detected. Analysis of combinations of the remaining alleles showed that: (i) two such plasmids were singlelocus variants (SLVs) of ST12, having the same allele variants; (ii) one plasmid was an SLV of ST2; and (iii) one plasmid had nearest matches in the pMLST database in only three loci (Table 1 ). IncI1/ ST12 was identified in nine isolates from all three host species. One human and four canine plasmids yielded indistinguishable RFLP profiles using PstI but the human plasmid differed by three bands using EcoRV ( Figure S1 , available as Supplementary data at JAC Online). RFLP subtyping of IncFII plasmids revealed the presence of indistinguishable plasmids in two canine isolates, while the remaining four plasmids yielded unique restriction profiles ( Figure S2 , available as Supplementary data at JAC Online).
Co-transfer of resistance to non-b-lactam antimicrobials was observed for 18% of the plasmids. All IncA/C plasmids co-transferred resistance to tetracyclines, and three IncI1 plasmids co-transferred resistance to trimethoprim/sulfamethoxazole (Table 1) . Plasmids belonging to other incompatibility groups and non-typeable plasmids did not transfer resistance to any of the antimicrobials tested.
Discussion
To the best of our knowledge, this study is the first One Health attempt to compare plasmids harbouring bla CMY-2 in E. coli isolated from human and companion animal infections within a defined geographical area. Notably, bla CMY-2 occurred at significantly higher frequency in companion animal isolates (85%) than in human isolates (14%), confirming that this resistance determinant is common in canine and feline E. coli infections in the USA. 8 The higher prevalence of bla CMY-2 in companion animals compared with humans could reflect the patterns of b-lactam consumption in small animal veterinary practice, where use of first-generation cephalosporins and amoxicillin/clavulanic acid is widespread. It has been previously hypothesized that the intensive use of cefalexin may have favoured dissemination of bla CMY-2 in the dog population. 7 The plasmid population was heterogeneous, with IncI1 plasmids being predominant in nearly half of the isolates tested. Most incompatibility groups detected in this study, especially IncA/C and IncFII, have been previously associated with CMY-2 in different host species worldwide.
2,16 However, we also detected a novel association with the IncL/M plasmid backbone in two human isolates and rare associations with IncI2 and IncB/O plasmid backbones in canine isolates. The authors are aware of single reports of bla CMY-2 on an IncI2 plasmid in a porcine Salmonella Heidelberg strain from the USA 17 and on IncB/O plasmids in poultry isolates from Japan. 18 The high diversity of plasmid types carrying bla CMY-2 emphasizes the mobility of this b-lactamaseencoding gene, which has previously been associated with ISEcp1-mediated transposition. 19 Genetic relatedness across host species was limited to IncI1/ ST12 plasmids of 90 kb, which have been reported in E. coli and Salmonella isolates from humans and poultry in diverse countries. 4, 5 Nevertheless, the only IncI1/ST12 plasmid originating from a human patient could be distinguished from related plasmids of canine origin by EcoRV RFLP. An SLV of ST12 was found in another human patient and in a dog. These plasmids may have originated from a common ancestor, although they were clearly distinguishable by size.
A limitation of the study is that isolates producing both AmpC b-lactamase and ESBL might be excluded on the basis of the criteria used for strain selection. However, our focus on AmpC b-lactamase enabled analysis of a relatively large number of CMY-encoding plasmids (n¼ 68) compared with previous studies on plasmids mediating cephalosporin resistance in E. coli of animal origin. 6 This approach, focused on AmpC b-lactamase, resulted in a variety of original findings. A novel CMY b-lactamaseencoding gene designated as bla CMY-108 was detected in two human isolates. Based on amino acid identity, this novel bla CMY-2 -harbouring plasmids in clinical E. coli, USA Bortolaia et al.
b-lactamase was more closely related to CMY-39 and CMY-80 (98.7%) than to CMY-2 (97.6%). The findings of plasmid types that had not (IncL/M) or had only rarely (IncI2 and IncB/O) been associated with CMY-2 previously and of several new IncI1 pMLST types and non-typeable plasmids indicate that the diversity of plasmid backgrounds was only partly explored prior to this study. The high level of genetic diversity observed in plasmids encoding CMY-2 represents an evolutionary advantage that could facilitate further spread of this b-lactam resistance determinant in the years to come as a consequence of the widespread use of b-lactams in both human and veterinary medicine. Co-selection by antimicrobials other than b-lactams seems to play a minor role since only a minority of plasmids harbouring bla CMY-2 carried additional resistance genes.
In conclusion, this study shows that plasmids carrying bla CMY-2 in clinical E. coli isolates from humans, dogs and cats in the Midwestern USA are highly heterogeneous, suggesting limited exchange between companion animals and humans. However, the design of this study was not particularly suited to the detection of zoonotic transmission of bla CMY-2 due to the low proportion of human CMY-2-producing isolates, the long period and the wide geographical area covered by the study. We did not examine the genetic background of CMY-2-producers because bla CMY-2 is usually not linked to specific E. coli lineages 20 and primarily spreads by horizontal transfer of plasmids. Moreover, strain typing would have not added information on zoonotic transmission since animal and human isolates were epidemiologically unrelated on the basis of their plasmid content. bla CMY-2 -harbouring plasmids in clinical E. coli, USA
